You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金城醫藥(300233.SZ):注射用頭孢唑林鈉(0.25g)獲藥品補充申請批件
格隆匯 03-05 18:02

格隆匯3月5日丨金城醫藥(300233.SZ)公佈,公司控股資子公司廣東金城金素製藥有限公司於近日收到國家藥品監督管理局核准簽發的注射用頭孢唑林鈉(0.25g)《藥品補充申請批件》。

頭孢唑林鈉(Cefazolin Sodium)是第一代頭孢菌素,抗菌譜廣,適用於治療敏感細菌所致的支氣管炎及肺炎等呼吸道感染、尿路感染、皮膚軟組織感染、骨和關節感染、敗血症、感染性心內膜炎、肝膽系統感染及眼、耳、鼻、喉科等感染,也可作為外科手術前的預防用藥,降低受污染或潛在污染患者的某些術後感染的發生率。

公司稱,此次獲得注射用頭孢唑林鈉補充申請批件,增加了注射用頭孢唑林鈉兒童用規格0.25g,且為國內首家上市,填補了國內市場空白,使藥品使用更加科學合理,降低了抗生素耐藥性的發生概率;增加了注射用頭孢唑林鈉1.0g規格,彌補了現有單一規格的問題,進一步豐富了公司產品線,同時提高製劑質量標準,有利於提高注射用頭孢唑林鈉的市場競爭力,該產品上市後將對公司產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account